T Cell Lymphomas
Conference Coverage
Getting hematologic cancer drugs on the fast track
In 2017, the FDA approved 17 agents for new or expanded indications for hematologic malignancies, including one agent for anaplastic large cell...
Conference Coverage
T-cell lymphoma therapies on the horizon
LA JOLLA, CALIF. – Three new agents are in the pipeline for T-cell lymphoma.
Conference Coverage
MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL
ATLANTA – Mogamulizumab topped vorinostat in terms of overall response to treatment and on several quality of life scales
News
FDA approves brentuximab vedotin for primary cutaneous anaplastic large cell lymphoma
Approval was based on a 56% objective response rate for brentuximab vedotin vs. 12% for physician’s choice of methotrexate or bexarotene in a...
From the Journals
Study shows childhood IBD increased cancer risk in adulthood
Childhood inflammatory bowel disease was associated with significant increases in the risk of cancer in later life.
CME
Clinical Endpoints in PTCL: The Road Less Traveled
Conference Coverage
Phase III trial: VZV protects auto-HCT patients
ORLANDO – An inactivated VZV vaccine for adults undergoing autologous hematopoietic stem cell transplantation has proven safe and effective.
Conference Coverage
Neuropathic pain puts cancer survivors out of work
Chronic neuropathic pain is a barrier to employment for many cancer survivors.
Conference Coverage
Brentuximab vedotin beat methotrexate, bexarotene in cutaneous T-cell lymphoma
SAN DIEGO – For patients with CD30 expressing cutaneous T-cell lymphoma, antibody-drug conjugate therapy with brentuximab vedotin significantly...
News
‘Meaningful’ antitumor activity with lenalidomide monotherapy in ATL
Key clinical point: Lenalidomide demonstrated clinical activity with acceptable toxicity in recurrent or relapsed ATL. Major finding: The overall...
News
Pretransplantation mogamulizumab for ATLL raises risk of GVHD
Key clinical point: The use of mogamulizumab before allogeneic hematopoietic stem-cell transplantation in aggressive adult T-cell leukemia/...